Basal Insulin

Drug identity checked against registry records

Also recorded as Abasaglar®; Basaglar®; Lantus®; Levemir®; Semglee®; Toujeo®; Tresiba®; insulin degludec; insulin detemir; insulin glargine

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Afrezza® INHALE-1 Study in PediatricsNCT04974528Mannkind CorporationPhase 3Completed2024-10-03Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.